Futura Medical Regulatory News (FUM)

Futura Medical plc

("Futura" or "the Company")

Remuneration of Non-Executive Directors

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces the introduction of a revised policy for the remuneration of its Non-Executive Directors including the Chairman Designate, John Clarke, under which they will receive approximately 30 per cent of their remuneration in the Company's ordinary shares.

Following a meeting yesterday of the Company's Remuneration Committee, it has been agreed that the shares for the current year's Non-Executive Directors' remuneration will be awarded at 84.10 pence per share, being the average closing mid-price of the last 10 trading days. The Non-Executive Directors will receive the shares at the end of the 2012 financial year.

In future, shares that form part of Non-Executive Directors' remuneration will be awarded at the end of the financial year at a share price based on the average closing mid-price for the final 10 trading days of the previous financial year.

Full details of Non-Executive Directors' remuneration will be included in the Company's Annual Report & Accounts.

For any further information please contact:

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com